공시 • Feb 15
Alterola Biotech, Inc. announced delayed 10-Q filing On 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Nov 15
Alterola Biotech, Inc. announced delayed 10-Q filing On 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 15
Alterola Biotech, Inc. announced delayed 10-Q filing On 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jun 29
Alterola Biotech, Inc. announced delayed annual 10-K filing On 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Feb 15
Alterola Biotech, Inc. announced delayed 10-Q filing On 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Nov 15
Alterola Biotech, Inc. announced delayed 10-Q filing On 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Oct 18
Alterola Biotech, Inc. Announces Executive Changes Alterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company. 공시 • Aug 17
Alterola Biotech, Inc. announced delayed 10-Q filing On 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jun 30
Alterola Biotech, Inc. announced delayed annual 10-K filing On 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. New Risk • Jun 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap). 공시 • Nov 16
Alterola Biotech, Inc. announced delayed 10-Q filing On 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Oct 05
Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI). Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022.
Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022. 공시 • Aug 17
Alterola Biotech, Inc. announced delayed 10-Q filing On 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Feb 16
Alterola Biotech, Inc. announced delayed 10-Q filing On 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 17
Alterola Biotech, Inc. announced delayed 10-Q filing On 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.